2',3'-isopropylidene-N6-(R)-(3-tetrahydrofuranyl)adenosine | 309725-38-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2',3'-isopropylidene-N6-(R)-(3-tetrahydrofuranyl)adenosine
• 英文别名: [(3aR,4R,6R,6aR)-2,2-dimethyl-4-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
• CAS: 309725-38-0
• 化学式: C₁₇H₂₃N₅O₅
• 分子量: 377.4
• InChiKey: VPMQNMAUBYYNEF-ZGOQAQPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2',3'-isopropylidene-N6-(R)-(3-tetrahydrofuranyl)adenosine 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 Methyl-carbamic acid (3aR,4R,6R,6aR)-2,2-dimethyl-6-{6-[(R)-(tetrahydro-furan-3-yl)amino]-purin-9-yl}-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester
  参考文献：
  名称：

  Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

  摘要：

  The SAR for the affinity to the A, adenosine receptor and relative intrinsic efficacy (IE, [S-35]-GTPgammaS binding) of a series of 5'-carbamate and 5'-thionocarbamate derivatives of tecadenoson is described. Based on this SAR, selected compounds were evaluated in guinea pig isolated hearts to determine whether they were partial or full agonists with respect to their negative dromotropism, an A(1) AdoR mediated effect. Progress towards obtaining a partial A(1) AdoR agonist to potentially control ventricular rate during atrial fibrillation has been made with the discovery of several potent partial A(1) AdoR agonists (compounds 13, 14, and 17). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.094
• 作为产物：
  描述：

  2,3,5-三-O-乙酰基-6-氯嘌呤-9-β-D-呋喃核糖苷 在 camphor-10-sulfonic acid 、 氨 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 丙酮 为溶剂， 生成 2',3'-isopropylidene-N6-(R)-(3-tetrahydrofuranyl)adenosine
  参考文献：
  名称：

  选择性A 1腺苷受体激动剂的基于结构的设计，合成和体内抗伤害作用

  摘要：

  我们以前的工作发现，在腺苷衍生物中结合适当的5'-和N 6-取代可导致高度选择性的人A 1腺苷受体（hA 1 AR）激动剂或高效的双重hA 1 AR激动剂和hA 3 AR拮抗剂。为了探索新颖的双腺苷受体配体，合成了一系列N 6-取代的5'-吡唑基-腺苷和2-氯-腺苷衍生物，并在所有AR中体外测定。所述Ñ 6 - （±） -内型-norbornyl衍生物12是最有效的和选择性A处1AR在福尔马林试验中可作为镇痛药有效，但5'-吡唑基系列化合物均未在hA 1和hA 3 AR处表现出双重行为。分子建模研究合理化了一系列新的A 1 AR激动剂的结构-活性关系和选择性。有趣的是，假设了N 6-四氢呋喃基衍生物14的意外的反向结合模式，以解释其对A 1 AR的低亲和力。

  DOI：

  10.1021/acs.jmedchem.7b01399

文献信息

• Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents
  作者：Christopher F. Morrison、Elfatih Elzein、Bob Jiang、Prabha N. Ibrahim、Timothy Marquart、Venkata Palle、Kevin D. Shenk、Vaibhav Varkhedkar、Tenning Maa、Lin Wu、Yuzhi Wu、Dewan Zeng、Irving Fong、David Lustig、Kwan Leung、Jeff A. Zablocki

  DOI：10.1016/j.bmcl.2004.04.096

  日期：2004.7

  Atrial fibrillation (AF) is the most commonly encountered sustained clinical arrhythmia with an estimated 2.3 million cases in the US (2001). A, adenosine receptor agonists can slow the electrical impulse propagation through the atrioventricular (AV) node (i.e., negative dromotropic effect) resulting in prolongation of the stimulus-to-His bundle (S-H) interval to potentially reduce ventricular rate. Compounds that are full agonists of the A, adenosine receptor can cause high grade AV block. Therefore, it is envisioned that a compound that is a partial agonist of the A, adenosine receptor could avoid this deleterious effect. 5' Phenyl sulfides (e.g., 17, EC50 = 1.26 muM) and phenyl ethers (e.g., 28, EC50 = 0.2 muM) are partial agonists with respect to their AV nodal effects in guinea pig isolated hearts. Additional affinity, GTPgammaS binding data suggesting partial activity of the A(1) adenosine receptor, and PK results for 5' modified adenosine derivatives are shown. (C) 2004 Elsevier Ltd. All rights reserved.
• [EN] PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] DERIVES PURIQUES SERVANT D'AGONISTES DES RECEPTEURS DE L'ADENOSINE A1, ET LEURS PROCEDES D'UTILISATION
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2005117910A3

  公开（公告）日：2006-07-13
• Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A₁ Adenosine Receptor Agonists
  作者：Riccardo Petrelli、Mirko Scortichini、Carmela Belardo、Serena Boccella、Livio Luongo、Fabio Capone、Sonja Kachler、Patrizia Vita、Fabio Del Bello、Sabatino Maione、Antonio Lavecchia、Karl-Norbert Klotz、Loredana Cappellacci

  DOI：10.1021/acs.jmedchem.7b01399

  日期：2018.1.11

  N6-substitution in adenosine derivatives leads to the highly selective human A1 adenosine receptor (hA1AR) agonists or highly potent dual hA1AR agonists and hA3AR antagonists. In order to explore novel dual adenosine receptor ligands, a series of N6-substituted-5′-pyrazolyl-adenosine and 2-chloro-adenosine derivatives were synthesized and assayed in vitro at all ARs. The N6-(±)-endo-norbornyl derivative 12 was

  我们以前的工作发现，在腺苷衍生物中结合适当的5'-和N 6-取代可导致高度选择性的人A 1腺苷受体（hA 1 AR）激动剂或高效的双重hA 1 AR激动剂和hA 3 AR拮抗剂。为了探索新颖的双腺苷受体配体，合成了一系列N 6-取代的5'-吡唑基-腺苷和2-氯-腺苷衍生物，并在所有AR中体外测定。所述Ñ 6 - （±） -内型-norbornyl衍生物12是最有效的和选择性A处1AR在福尔马林试验中可作为镇痛药有效，但5'-吡唑基系列化合物均未在hA 1和hA 3 AR处表现出双重行为。分子建模研究合理化了一系列新的A 1 AR激动剂的结构-活性关系和选择性。有趣的是，假设了N 6-四氢呋喃基衍生物14的意外的反向结合模式，以解释其对A 1 AR的低亲和力。
• Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)
  作者：Venkata P Palle、Vaibhav Varkhedkar、Prabha Ibrahim、Hiba Ahmed、Zhihe Li、Zhenhai Gao、Mark Ozeck、Yuzhi Wu、Dewan Zeng、Lin Wu、Kwan Leung、Nancy Chu、Jeff A Zablocki

  DOI：10.1016/j.bmcl.2003.09.094

  日期：2004.1

  The SAR for the affinity to the A, adenosine receptor and relative intrinsic efficacy (IE, [S-35]-GTPgammaS binding) of a series of 5'-carbamate and 5'-thionocarbamate derivatives of tecadenoson is described. Based on this SAR, selected compounds were evaluated in guinea pig isolated hearts to determine whether they were partial or full agonists with respect to their negative dromotropism, an A(1) AdoR mediated effect. Progress towards obtaining a partial A(1) AdoR agonist to potentially control ventricular rate during atrial fibrillation has been made with the discovery of several potent partial A(1) AdoR agonists (compounds 13, 14, and 17). (C) 2003 Elsevier Ltd. All rights reserved.